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The present study assessed the therapeutic efficacy of glucosamine hydrochloride against collagen-induced arthritis in female Dark
Agouti rats (DA). Arthritis was induced by intradermaly injecting a collagen and complete Freund’s adjuvant suspension atmultiple
sites in the rat at a dose of 4mg/kg of body weight and thereafter followed by twomore boosters of the same dose, after the 1st week
and 2nd week of primary immunization. After 21 days from the day of primary immunization, the arthritic group rats were given
oral supplementation of glucosamine hydrochloride at a dose of 300mg/kg of body weight until day 45.The arthritic group treated
with glucosamine hydrochloride from day 21 to day 45 showed significant reduction in arthritic histopathological changes of the
joints, reduction in paw thickness and also a significant decrease in C-reactive protein and TNF-alpha in the serum. Treatment
with 300mg/kg of glucosamine hydrochloride was able to reverse the arthritic changes, hence suggesting that glucosamine has a
therapeutic effect against collagen-induced arthritis.
1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory autoim-
mune disease. It is a destructive polyarthropathy that leads to
disability and immobility [1]. The main characteristic feature
of RA is swelling of the joints, and it is also sometimes
manifested in other organ systems in severe disease states.
Some of the common physical symptoms of RA are swelling
of joint areas, painful and stiff joints, fatigue, malaise,
weight, loss and sometimes even depression [2]. The exact
aetiopathogenesis of RA is not known. Risk factors such
as genetic predisposition and environmental factors like
cigarette smoking [3], microbial infections [4], and blood
transfusions [5] will lead to the activation of CD 4+ T
helper cells, which will lead to the stimulation of various
cells in the joints that produce cytokines and inflammatory
mediators that play an important role in the development of
RA. Inflammatory mediators like matrix metalloproteinases
(MMP) and cell adhesion molecules (CAMs), together with
cytokines like tumor necrosis factor-alpha (TNF-𝛼) and
interleukin-1 (IL-1), lead to joint destruction in RA patients
[2, 6].
At present, there are few treatment options available
for RA. Nonsteroidal anti-inflammatory drugs (NSAIDs),
cyclooxygenase-2-selectiveNSAIDs [7], glucocorticoids, bio-
logical response modifying agents, and disease modifying
antirheumatic drugs (DMARDs) are prescribed by physicians
currently as single therapy or combined multiple drug ther-
apy [8]. It has beenshown to slow the disease progression
in some cases, but itis not shown to completely reverse
symptoms of RA and prevent the disease onset.
Glucosamine is an amino monosaccharide, which is a
derivative of glucose. It is naturally found in mucous secre-
tions, connective tissue, skin, tendons, and ligaments, and it is
found in highest concentration in cartilage [9]. With age, the
production of glucosamine by the body will decrease; hence,
it needs to be replenished by the use of oral glucosamine
supplements. Currently glucosamine is used in the therapy
for osteoarthritis (OA) to synthesize glycosaminoglycans
(GAGs) [10]. Studies have also shown that glucosamine
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supplementation can repair the cartilage to some extent in
OA [11]. Recent studies have also shown that glucosamine
has immunosuppressive properties, which can successfully
suppress the activity of T-lymphocytes and dendritic cells
[12] which are involved in adaptive immune responses. The
present study investigated the efficacy of glucosamine against
collagen-induced arthritis in female Dark Agouti (DA) rats.
2. Methods
2.1. Reagents. Glucosamine hydrochloride (D-(+)-
glucosamine hydrochloride; G4875; C
6
H
13
NO
5
⋅HCl;
mol wt: 215.63 g/mol; Sigma), complete Freund’s adjuvant
(CFA), type II collagen, and all other analytical chemicals
used for the experiment were obtained from Sigma Aldrich
(St. Louis, MO, USA). The dose received by the treatment
group in this study was 300mg/kg/rat [13].
2.2. Animals. Female Dark Agouti (DA) rats [14] of 6–
10 weeks old were obtained from the Institute of Medical
Research, Kuala Lumpur, Malaysia. The rats were kept in
individual ventilation cages throughout the study. Rats were
housed in standard laboratory conditions with 12:12 light-
dark cycle with free access to food and water throughout
the study. There were three groups of animals in this study,
each group containing 10 rats. Group 1—control without any
treatment, Group 2—arthritis only group, and Group 3—
arthritis with glucosamine hydrochloride (300mg/kg/rat).
All the experimental procedures were in accordance with
the guidelines for the care and use of laboratory animals,
and approval from the Institutional Research and Ethics
Committee was taken prior to the experiments.
2.3. Collagen-Induced Arthritis. Type II collagen from
chicken tracheal cartilage obtained from Sigma Aldrich
(USA) was dissolved in 0.1M of cold acetic acid. The
dissolved collagen was then emulsified with an equal volume
of complete Freund’s adjuvant (CFA) (Sigma Aldrich, USA).
Each rat was injected intradermally with 4mg/kg of collagen
suspension at multiple joint areas [15] and also at the base of
the tail [16]. A booster dose injection was given after a week
following primary immunization, and a second booster was
administered 15 days after first booster injection.
2.4. Treatment of Animals with Glucosamine Hydrochloride.
Glucosamine hydrochloride was administered orally using
a rodent feeding tube with a dose of 300mg/kg/rat. The
treatment was started 21 days after the primary immunization
and continued until day 45.
2.5. Measurement of BodyWeight and PawThickness Changes.
The severity of arthritis in the animals was evaluated by
quantifying the changes in paw thickness in the front and
hind paws. Thickness was measured using a digital caliper
once every five days (there was not any significant change
in the paw thickness during the 5-day period in the earlier
studies done in our laboratory) until day 45.The body weight
changes of the rats were also recorded once every five days
during the study period.
2.6. Collection of Plasma. At the end of the experimental
period, animals were anesthetized with sodium pentobarbital
(40mg/kg body weight) and blood samples were collected
by cardiac puncture. A volume of 3-4mL of blood was
collected in a vacutainer tube which contained EDTA. These
tubes were then centrifuged at 5000 rpm for 10 minutes at
4∘C. The plasma was separated and stored at −30∘C for
further investigations. Rats were sacrificed with an overdose
of anesthesia, and limbs were harvested for joint histopathol-
ogy.
2.7. C-Reactive Protein and Tumour Necrosis Factor-Alpha
Assay. The C-reactive protein (CRP) and tumour necrosis
factor-alpha (TNF-𝛼) concentration level in the plasma were
quantified using a commercial kit according to the standard
protocol recommended by the manufacturer (Assay Pro,
USA, and eBioscience, USA). In the C-reactive protein assay,
25 𝜇L of the standards was added to the relevant wells,
and 25 𝜇L of the diluted samples were added in duplicates.
Biotinylated rat CRP (25 𝜇L) was added to all wells, gently
mixed, and kept for incubation for 2 h. After incubation, the
plate was washed using wash buffer and 50𝜇L of diluted
streptavidin peroxidase conjugate was added and incubated
for 30min. The plate was washed and filled with 50𝜇L chro-
mogen substrate and left for 10min for color development. A
stop solution was added, and the absorbance produced was
immediately read at 450 nm. The CRP concentration of each
of the samples was calculated in 𝜇g/mL based on the standard
curve obtained. The concentration of TNF-𝛼 in the plasma
was quantified using a commercial rat TNF-𝛼 ELISA kit.
The previous night, the plate was coated with diluted capture
antibody as described in the study protocol providedwith this
kit. Then, 100 𝜇L of the standards were added to the standard
wells and 100𝜇L of samples was added to the sample’s wells in
duplicates. The plate was incubated at room temperature for
2 h. After washing with buffer, 100𝜇L of the diluted detection
antibody solution was added to all wells, and the plate was
incubated for 1 h at room temperature. Afterwards, 100𝜇L
of the diluted avidin HRP was added to all the wells and
incubated at room temperature for 30min. Following this,
100 𝜇L of the substrate solution was added to all the wells.
Finally, 50𝜇L of 2NH
2
SO
4
was added and the absorbancewas
read at 450 nm.
2.8. Histopathological Analysis. The flesh from the joints was
cleared away, and the joint sample was stored in 10% formalin
solution for three weeks in specimen bottles. The joint sam-
ples were stored in a decalcification agent for 48 hours before
processing. The decalcified samples were processed using
Leica TP 1020 tissue processor machine and embedded in
paraffinblocks using a Leica EG 1160 tissue embedding center.
The haematoxylin and eosin stained slides were visualized
and analyzed using a Nikon Eclipse 80i microscope. The
joints were evaluated and analyzed according to a grading
system adopted from a previous study [17] (Table 1).
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Table 1: The histopathological characteristics observed in a joint affected by rheumatoid arthritis and the grading system for the analysis of
joints.
0 1 2 3
Oedema Nil Mild Moderate Severe
Cellular
Infiltration Nil Mild scattered infiltration Lymphocytes and macrophages
Sheets of inflammatory
cells/granulomas/MNG cells
Joint space No narrowing Mild narrowing Moderate narrowing with very littleintermeningeal space Total obliteration of joint space
Synovial
hyperplasia Nil Mild Moderate Extensive
Fibrosis Nil Mild Moderate Extensive/severe
Erosion Absent Present
2.9. Statistical Analysis. Statistical analysis was carried out
by one-way analysis of variance (ANOVA) using the SPSS.
The histology of the joints and the plasma levels of C-
reactive protein and TNF-𝜇 were also statistically analyzed
for nonparametric measures using theMann-Whitney𝑈 test.
𝑃 < 0.05 was considered statistically significant.
3. Results
3.1. Effects on the Body Weight. In the arthritis only group,
therewas a significant decrease in the bodyweight (𝑃 < 0.05).
Arthritis rats that had oral supplementation of glucosamine
showed a steady increase in the bodyweight initially, but there
was a significant decrease in the weight gain after 15 days
until day 25, but weight increased significantly after day 25
in these rats. Even though there was an increase in the body
weight with glucosamine treatment, the weight change did
not increase significantly compared to control rats (Figure 1).
3.2. Effects on Gross Arthritic Symptoms. A significant
increase (𝑃 < 0.05) in the hind paw thickness was observed
in the arthritic rats from day 1 to day 45 when compared
to control rats. Glucosamine treatment depicted a significant
reduction (𝑃 < 0.05) in the paw thickness compared to
arthritis alone at the 45th day.Therewas severe swelling of the
joints in the hind paw in the arthritic rats. The joints showed
redness and ankylosis. The group of rats that were started on
oral supplementation of glucosamine showed only mild to
moderate signs and symptoms of arthritis, when compared
to the arthritis alone group.The swelling of the ankle joints in
the hind paw was significantly less in the treated group than
in the arthritis only group (Figures 2 and 3).
3.3. Effects of Glucosamine on C-Reactive Protein. A sig-
nificant increase (𝑃 < 0.05) in C-reactive protein level
was seen in arthritis only rats until 45 days compared to
control rats.The level of C-reactive protein concentrationwas
significantly reduced (𝑃 < 0.05) after oral supplementation of
glucosamine (Figure 4).
3.4. Effects of Glucosamine on TNF-𝛼. A significant increase
(𝑃 < 0.05) in the TNF-𝛼 level was seen in the arthritis
alone rats compared to controls. There was a significant
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Figure 1: Changes in body weight in the two experimental groups.
(a) 𝑃 < 0.05—control with other groups; (b) 𝑃 < 0.05—arthritis
with arthritis + glucosamine.
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Figure 2: Changes in paw thickness. (a) 𝑃 < 0.05—control with
other groups; (b) 𝑃 < 0.05—arthritis with arthritis + glucosamine.
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Figure 3: Paw edema—(a) hind paw and ankle of control rats; (b) arthritis control showing severe swelling at the joints in both ankles; (c)
hind paw and ankle joint of arthritic rat with glucosamine.
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Figure 4: Plasma concentration of C-reactive protein. (a) 𝑃 <
0.05—control with other groups; (b) 𝑃 < 0.05—arthritis with
arthritis + glucosamine.
decrease in TNF-𝛼 levels in the plasma of the glucosamine
treated group (𝑃 < 0.05) than the untreated arthritis only
control group. Glucosamine has reduced the concentration
of this inflammatorymarker significantly in the treated group
(Figure 5).
3.5. Histopathological Changes. To further evaluate the
treatment aspect of glucosamine hydrochloride against
rheumatoid arthritis, histopathological analysis was done as
described in Table 1, which is a method adapted from the
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Figure 5: Plasma levels of TNF-𝛼. (a) 𝑃 < 0.05—control with other
groups; (b) 𝑃 < 0.05—arthritis with arthritis + glucosamine.
previous study [17]. Arthritis only group showed a sever-
ity of grade three, while the glucosamine treated arthritic
group had pathological characteristics of grade 1–0 severities
(Figure 5).
Synovial hyperplasia is observed in the untreated arthritis
only group, which appeared to have developed extensive
oedema causing the joint space to narrow. The group treated
with glucosamine showed the best results, that is, the reversal
of synovial hyperplasia as in these rats and the joint appeared
to be similar to a normal joint (Figure 6). There were healthy
regenerative synovium and areas of fibrosis, angiogenesis,
and fibroblasts proliferation with accumulation of collagen,
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Figure 6: Histopathological analysis of joint morphology (200x). Control synovium (Aa) and joint (Ab); arthritis joint narrowing (Ba) and
synovial congestion (Bb); arthritis with glucosamine joint (Ca) and reduced synovial congestion (Cb).
suggesting good wound healing. In the untreated arthritis
rats, the joints had extensive oedema with narrowing of the
space. The surface of the joint margins showed degenerative
changes. In the glucosamine treated arthritic groups, the
synovial space was adequate with focal areas of degenerative
changes (Figure 6).
In the untreated arthritic group, the synovium showed
hyperplasia and increased angiogenesis and fibrosis.The joint
vascularity showed congestion with dilated blood vessels.
The group treated with glucosamine showed no synovial
congestion compared to the other two groups (Figure 6).
There was an extensive inflammation with pannus forma-
tion in several places among untreated arthritic rats. The
pannus was composed of a granulomatous accumulation of
chronic inflammatory cells like lymphocytes, plasma cells,
and macrophages and multinucleate giant cells seen in the
untreated arthritic group.The glucosamine treated group had
mild to moderate inflammation (Figure 6).
4. Discussion
Collage-induced arthritis (CIA) was induced when type II
collagen was emulsified with complete Freund’s adjuvant
(CFA) and injected into the base of the rat’s tail. In this animal
model of arthritis study, female Dark Agouti or DA rats, aged
6–10 weeks, are used. Complete Freund’s adjuvant injection
will induce an immunological hypersensitivity reaction to
collagen in the rats, leading to the development of systemic
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effects of chronic rheumatoid arthritis [18]; therefore, the
collagen-induced arthritis DAmodel shows most similarities
to the human rheumatoid arthritis. Dark Agouti rats are
especially susceptible to rheumatoid arthritis. These rats
develop a chronic and severe form of autoimmune arthritis,
which leads to permanent bone destruction and ankylosis
of affected joints. Arthritis-induced joint destruction in DA
rats is believed to be the consequence of cell mediated
immune responses, which mimic the pathogenesis of human
rheumatoid arthritis [19–21].
This study evaluated the oral administration of glu-
cosamine on histopathological and inflammatory markers.
The dose of glucosamine used in this study is 300mg/kg
body weight, which would give an approximate serum level
of glucosamine (0.05mM) similar to that in humans [13, 22].
Because of the substantial amount of gastrointestinal loss in
rats, a higher daily dose of glucosamine is usually selected
in animal models of arthritis. Glucosamine is a naturally
occurring chemical component that is found in its highest
concentration in joint areas [23, 24].
Our study showed a significant decrease in body weight
around the 25th day in arthritis rats as compared to the
normal control. Glucosamine treatment (300mg/kg) showed
significant recovery in the body weight during the last 10
days of the treatment when compared to their arthritic
controls. Glucosamine treatment also suppressed the paw
thickness from day 20 to day 45. Glucosamine acts at the
joints by being incorporated by the chondrocytes into the
cartilage. Here it will stimulate the synthesis of physiological
proteoglycans and also will decrease the activity of matrix
metalloproteinases, which are catabolic enzymes that attack
the cartilage. Glucosamine can also inhibit the degradation
of cartilage, which is induced through IL-1 [21, 25]. Thus,
glucosamine acts as a substrate for the biosynthesis of
mucopolysaccharides in bones and joints, which will aid in
restoring damaged cartilage.
Several studies have implicated TNF-𝛼 as a contributor to
cellular damage in collagen-induced arthritis. The increased
concentration of this cytokine in circulation can be inter-
preted as a progression of cartilage cell injury [26, 27]. The
anti-inflammatory action of glucosaminemight have lowered
circulating TNF-𝛼 concentration and consequently reduced
the joint damage. C-reactive protein is produced under
conditions of inflammation in cartilage and bone and is a
useful biomarker in the evaluation of disease progression and
response to therapeutic intervention in a number of inflam-
matory disorders, including RA. Higher concentration of C-
reactive protein will point toward increased joint changes
in arthritis [28]. In our study, it is shown that glucosamine
reversed inflammatory damage in joints when comparedwith
untreated arthritic rats.
Histopathological changes in our study correlated with
macroscopic observations, including changes in the paw
thickness. Arthritis only rats showed maximum degenerative
changes. A significant reduction in the joint changes was
observed in glucosamine treated groups. In the treated
rats, a reversal of many of the arthritis-induced histological
changes was observed. In terms of the joint analysis grading
system, the untreated arthritic rats mostly showed the grade
3 characteristics, which are of the most severity level, and
the glucosamine treated group showed the least severity
(grade 1-2). Observed protective effects may be due to
the inhibition of inflammatory mediators by glucosamine
[12].
Glucosamine acts at the joints and is known to effi-
ciently suppress the activity of T-lymphocytes and dendritic
cells, two crucial cells involved in immune responses [12].
Tumour necrosis factor-𝛼 (TNF-𝛼) and interleukin-1 (IL-1)
are produced by macrophages and synovial lining cells
and can be found in high concentrations in arthritis. Both
of these cytokines act synergistically in the production of
matrix metalloproteinase (MMP), expression of various cell
adhesionmolecules (CAMs), and secretion of prostaglandins
[6, 29]. The observed joint destruction could be because of
the accumulation of MMPs, and prostaglandins and glu-
cosamine treatment has suppressed the productions of these
inflammatory mediators. By suppressing joint inflammatory
responses, glucosamine prevents pannus formation. During
arthritis, the pannus becomes fibrosed and will have minimal
vascularization, and this will result in the destruction of
the cartilage. Histopathology revealed reduced pannus and
bony ankylosis in DA rats with glucosamine treatment
confirming the protective effect of glucosamine against
joint damage. This supports some of the other studies that
have shown that glucosamine supplementation can repair
cartilage damage to some extent in osteoarthritis patients
[10, 11].
Thus, our study evaluated the effect of oral administration
of glucosamine to Dark Agouti rats on gross, biochemical,
and histopathological changes. Glucosamine treatment not
only suppressed joint swelling, it also reduced the inflam-
matory mediators like TNF-𝛼 and C-reactive proteins. There
was reduced histopathological change in the joints. These
observations support the view that glucosamine suppresses
the chronic inflammatory phase in collagen-induced arthri-
tis. Glucosamine exerts its anti-inflammatory effects by sup-
pressing the activation of inflammatory cytokines. A rapid
and significant beneficial effect of glucosamine was observed
against arthritis in DA rats in this study. Thus, the findings
confirmed the joint modifying and anti-inflammatory prop-
erties of glucosamine in collagen-induced arthritis.
5. Conclusion
In conclusion, the findings from this study demonstrate
that glucosamine effectively reduces the degree of edema
and inflammation caused by collagen-induced arthritis in
female Dark Agouti rats. Results also confirm glucosamine
as a therapeutic agent for the treatment of rheumatoid
arthritis. A dose-response study of glucosamine-induced
anti-inflammatory effects and its molecular mechanisms are
being investigated further.
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